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Abstract
Background: Apolipoprotein C3 (APOC3) modulates triglyceride metabolism through inhibition of lipoprotein lipase, but is
itself regulated by insulin, so that APOC3 represents a potential mechanism by which glucose metabolism may affect lipid
metabolism. Unfavorable lipoprotein profiles and impaired glucose metabolism are linked to cognitive decline, and all three
conditions may decrease lifespan. Associations between apolipoprotein C3 (APOC3) gene polymorphisms and impaired lipid
and glucose metabolism are well-established, but potential connections between APOC3 polymorphisms, cognitive decline
and diabetes deserve further attention.
Methods: We examined whether APOC3 single nucleotide polymorphisms (SNPs) m482 (rs2854117) and 3u386 (rs5128)
were related to cognitive measures, whether the associations between cognitive differences and genotype were related to
metabolic differences, and how diabetes status affected these associations. Study subjects were Hispanics of Caribbean
origin (n=991, aged 45–74) living in the Boston metropolitan area.
Results: Cognitive and metabolic measures differed substantially by type II diabetes status. In multivariate regression
models, APOC3 m482 AA subjects with diabetes exhibited lower executive function (P=0.009), Stroop color naming score
(P=0.014) and Stroop color-word score (P=0.022) compared to AG/GG subjects. APOC3 m482 AA subjects with diabetes
exhibited significantly higher glucose (P=0.032) and total cholesterol (P=0.028) compared to AG/GG subjects. APOC3
3u386 GC/GG subjects with diabetes exhibited significantly higher triglyceride (P=0.004), total cholesterol (P=0.003) and
glucose (P=0.016) compared to CC subjects.
Conclusions: In summary, we identified significant associations between APOC3 polymorphisms, impaired cognition and
metabolic dysregulation in Caribbean Hispanics with diabetes. Further research investigating these relationships in other
populations is warranted.
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Introduction
As individuals age, preserved cognitive function is associated
with favorable lipid and glucose profiles, and these phenotypic
traits often coexist in very long-lived individuals [1–3]. For
example, plasma high density lipoprotein cholesterol (HDL-C) is
positively correlated and triglycerides are negatively correlated
with cognitive ability in centenarians [1], and unimpaired
cognitive function is linked to reduced risk of death in elderly
individuals [4]. Normal glucose metabolism, as evaluated by
insulin sensitivity, is also characteristic of longer survival [3,5],
whereas diabetes increases mortality through increased cardiovas-
cular or cerebrovascular disease risk [6,7].
The favorable metabolic profiles and preserved cognitive
function associated with healthy aging may be linked through
common genotypes regulating lipoprotein metabolism such as
cholesterol ester transfer protein [2]. Conversely, unfavorable
metabolic profiles and cognitive decline which may be associated
with vascular disease may be related through alleles such as APOE
e4 [8]. Another candidate gene that has been implicated in
pathways influencing lipids, glucose metabolism and possibly
cognition is APOC3, which encodes apolipoprotein C-III [3,9].
APOC3 is a component of triglyceride-rich lipoproteins and is
an important modulator of plasma triglycerides [10]. Inhibition of
lipoprotein lipase by APOC3 and subsequent decreased triglyc-
eride clearance may lead to hypertriglyceridemia [11]. Activation
of endothelial cells and subsequent increased expression of
adhesion molecules by APOC3 may represent additional mech-
anisms by which the protein contributes to atherogenesis [12].
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the 39 untranslated region, formerly known as SstI, and m482, a
promoter single nucleotide polymorphism (SNP) located in an
insulin response element (IRE), have been associated with
alterations in both lipid and glucose metabolism [13–15]. APOC3
m482 has been shown to act synergistically with variants of two
other lipid regulators, CETP and APOE, to increase risk of
coronary artery disease [16].
APOC3 also plays a role in diabetes, in which elevated plasma
concentrations of both the apolipoprotein and triglycerides
increase vascular disease risk [7]. Triglycerides were reported to
be significantly higher for those with diabetes and carrying the
variant allele for the m482 SNP [17]. Diabetes also increases the
risk of cognitive impairment which is likely to be mediated, at least
in part, through dysregulation of lipid metabolism and impaired
vascular integrity [18]. However, with the exception of inconclu-
sive reports evaluating relationships between APOC3 and Alzhei-
mer’s disease [9,19], the extent to which APOC3 is associated with
cognitive impairment is largely unexplored. In the current study,
we investigated associations between two APOC3 SNPs (3u386 and
m482) and cognitive function, and explored the metabolic
measures which might underlie cognitive loss in a Caribbean
Hispanic population. We investigated these relationships in the
context of diabetes, which is characterized by metabolic
dysregulation and is associated with cognitive loss.
Methods
Ethics Statement
All research involving human participants was approved by the
authors’ institutional review board or equivalent committee(s) and
that board is named below. For research involving human
participants, informed consent was obtained and all clinical
investigation was conducted according to the principles expressed
in the Declaration of Helsinki. The Institutional Review Board at
Tufts University/New England Medical Center approved the
protocol of the current study.
Study Design and Subjects
Participants were recruited for a prospective two-year cohort
study of men and woman of Puerto Rican origin, aged 45–75
years, and living in the Boston, Massachusetts metropolitan area.
Data from the 2000 US Census were used to identify areas with a
high density of Hispanic individuals in the target age range. Most
participants were recruited through door-to-door enumeration.
Blocks were visited at least three times and up to six times on
different days of the week, including weekends, and at different
times of the day. Participants were also identified by random
approach at community festivals and other community events,
through referrals from those invited to participate and through
flyers distributed in the community. Eligibility requirements
included self-reported Puerto Rican origin, the ability to answer
interview questions in Spanish or English, living in the Boston area
and being in the target age range. Individuals were excluded if
serious health problems precluded answering interview questions,
if the Mini Mental Status Examination Score (MMSE) was #10 or
if they planned to move away from Boston within two years. Of
2004 individuals invited to participate, 1724 agreed to participate
and 1357 completed the baseline interview. Individuals declined to
participate due to lack of interest, lack of time or unwillingness to
undergo blood draw. Genotyping was performed on 991 subjects,
and analysis was limited to genotyped subjects.
Interviews to collect baseline demographic information, medical
history and dietary data were conducted in the participants’ homes
between 2004 and 2008 by trained bilingual staff. Anthropometric
data including height, weight, and waist circumference were
measured in duplicate consistent with the technique used by the
National Health and Nutrition Surveys. Blood was collected for
biochemical analyses and genetic analysis, and was stored at
280uC.
Genetic analysis
Genomic DNA was isolated from peripheral blood lymphocytes
by standard methods. The single nucleotide polymorphisms (SNP)
APOC3 3u386 (rs5128) and APOC3 m482 (rs2854117), and
(apolipoprotein E) APOE_C130R (rs429358) and APOE_R176C
(rs7412) were genotyped using the ABI TaqMan SNP genotyping
system 7900HT (Applied Biosystems, Foster City, California).
Linkage disequilibrium (LD) between the two SNPs was estimated
as a correlation coefficient (r
2) using Haploview software version
4.0 [20].
Population ancestry admixture
The study subjects reflect three ancestral populations, Europe-
an, Native American and African, which may be represented in
varying proportions for each individual. One hundred ancestral
markers were chosen to reduce confounding associated with
population stratification [21]. The programs STRUCTURE 2.2
[22] and IAE3CI [23] were used to calculate three admixture
values for each subject and achieved similar results [24].
Multivariate regression analysis models incorporate adjustment
for population admixture through the addition of two of the three
admixture variables as covariates.
Cognitive Assessment and Factor Analysis
Cognitive ability was assessed using standard neuropsycholog-
ical instruments administered in either Spanish or English,
depending on the subject’s preference.
Data reduction of cognitive test scores was conducted using
principal components analysis to address issues associated with
multiple testing. Interpretation of the resulting cognitive compo-
nents was completed using Varimax rotation. Components with
Eigen values greater than 1.0 were selected; cognitive tests that
had factor loadings equal to or greater than 0.40 were considered
to have primary loading on that factor. This analysis yielded three
cognitive components interpreted as (1) executive function
(planning, organization and multi-tasking), (2) memory, and (3)
attention. Each cognitive component had a mean of 0.0 and
standard deviation of 1.0. Composite variable were derived from
specific tests as follows: executive function (Stroop color naming,
Stroop word reading, Stroop color-word, verbal fluency, figure
copying, clock drawing), memory function (word list learning
immediate, word list learning delayed, word list learning percent
retention, word list learning delayed recognition) and attention/
concentration (verbal fluency, digit span forward, digit span
backward and serial sevens subtraction from the MMSE).
Statistical Analyses
All continuous variables were examined for normal distribution
and a logarithmic transformation was applied for plasma
triglycerides and glucose. The chi-square test was used to
determine whether genotype distribution was consistent with
Hardy-Weinberg equilibrium (HWE) expectations. Differences in
cognitive function based on genotype were evaluated in the
population in its entirety, using analysis of variance techniques.
Differences in cognitive and metabolic measures between subjects
with and without diabetes were evaluated using independent t-tests
APOC3 and Cognition
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and non-diabetics separately. The relationships between APOC3
genotypes and metabolic or cognitive measures were evaluated by
analysis of variance techniques. For analyses involving genotype,
three genotype groups were first considered to determine the most
appropriate model. For APOC3 m482 a recessive model was
applied and for APOC3 3u386 a dominant model was applied.
Multivariate regression models for cognitive measures included
control for potential confounders including age, sex, education,
income and ancestry admixture. Potential confounders for lipid
and glucose measures included age, sex, alcohol (never, past,
current), smoking (never, past, current), antilipemic medication,
waist circumference and ancestry admixture. SAS (Version 9.1 for
Windows) was used to analyze data. A P value of 0.05 was
considered statistically significant.
Results
Demographic, metabolic and genotypic data, divided by
diabetes status, are presented in Table 1 as unadjusted medians
with the range of minimum and maximum values. Compared to
those without diabetes, subjects with diabetes exhibited signifi-
cantly lower executive function (P,0.0001), lower memory
function (P=0.038), lower attention/concentration function
(P=0.045), total cholesterol, HDL-C and low density lipoprotein
cholesterol (LDL-C) (all P,0.0001), higher triglycerides
(P=0.0002), glucose, body mass index (BMI) and waist circum-
ference (all P,0.0001) and older age (P,0.0001). Minor allele
frequencies (MAF) of each SNP were 0.29 (APOC3 3u386) and
0.44 (APOC3 m482) and frequencies did not differ significantly
between subjects with and without diabetes. Genotype frequency
for APOC3 m482 did not deviate from HWE expectations but
APOC3 3u386 frequency was not consistent with HWE. Evalua-
tion of LD between the two SNPs revealed an r
2 value of 0.024,
indicating that SNPs were not in LD.
Cognitive differences were first evaluated in the population in its
entirety by APOC3 3u386 and APOC3 m482 genotype, and no
significant differences were found. Metabolic differences based on
genotype were not evaluated in the population as a whole. Instead,
based on the large number of highly significant cognitive and
metabolic differences between subjects with and without diabetes
(Table 1), we evaluated genotypic associations with phenotypic
traits separately (diabetics and non-diabetics) for APOC3 m482
(Table 2) and APOC3 3u386 (Table 3). Three genotype groups
were first considered to determine the most appropriate model.
For APOC3 m482 a recessive model was applied and for APOC3
3u386 a dominant model was applied. Cognitive measures were
evaluated by first testing for differences in overall functions
(executive, memory and attention/concentration functions), and
then continuing with appropriate individual test scores if
differences were detected at the overall function level. For both
SNPs, adjustment for ancestry admixture and for APOE e4 carrier
status were added as covariates to the models and these
adjustments did not alter significant relationships. We observed a
significant difference between APOC3 m482 genotypes (GG, AG
Table 1. Cognitive, metabolic and genotypic measures, by diabetic status.
Non-diabetic (n=583) Diabetic(n=408) P value
Composite Cognitive Measures
1
Executive Function 0.262 (23.22–2.88) 20.201 (22.83–2.19) ,.0001
Memory Function 0.119(24.03–2.37) 0.029 (24.04–2.40) 0.038
Attention/concentration 0.066(23.31–3.17) 20.040 (23.57–3.17) 0.045
Demographic
1
Age(y) 56(45–75) 59(45–75) ,.0001
Female n (%) 418(71) 294(72) 0.943
Metabolic Measures
1
Total cholesterol (mmol/L) 4.9(2.3–9.7) 4.4(2.3–9.2) ,.0001
LDL-C (mmol/L) 3.0(0.8–5.5) 2.4(0.8–5.8) ,.0001
Triglyceride (mmol/L) 1.4(0.4–19.9) 1.6(0.4–14.5) 0.0002
HDL-C (mmol/L) 1.2(0.5–3.0) 1.1(0.5–2.2) ,.0001
Glucose(mmol/L) 5.4(3.8–6.9) 7.8(2.9–32.6) ,.0001
BMI (kg/m
2) 30.2(17.0–59.9) 32.8(18.1–63.8) ,.0001
Waist (cm) 98(57–181) 105(67–167) ,.0001
Genotype
APOC3 m482
GG 174(30.7) 132(34) 0.288
AG 275(48.6) 196(50)
AA 117(20.7) 66(16)
APOC3 3u386
CC 318(57) 215(56) 0.614
GC 155(28) 102(26.6)
GG 84(15) 67(17.4)
1Reported as unadjusted median (range).
doi:10.1371/journal.pone.0005465.t001
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data not shown) but cognitive associations were stronger when a
recessive model was evaluated, and this model was used for all
further comparisons for this SNP (Table 2). For those with diabetes
but not for those without diabetes, executive function was lower in
AA subjects (homozygous for the minor allele) compared to GG
and AG subjects combined (P=0.009). Three component tests,
which were strongly correlated with executive function, were
evaluated and component scores for two of these (Stroop color
naming and Stroop color-word test) were lower in AA subjects
(P=0.014 for color naming and P=0.022 for color-word). Total
cholesterol (P=0.028) and fasting glucose (P=0.032) were higher
in AA subjects. No significant cognitive or metabolic differences
were observed for APOC3 m482 genotypes in subjects without
diabetes.
For APOC3 3u386, associations were also evaluated separately
in subjects with and without diabetes (Table 3). No significant
differences between genotypes were observed for any of the overall
cognitive measures in either group and no individual test scores
were evaluated. For metabolic measures for APOC3 3u386,
differences were most apparent in the context of a dominant
model, which was used for all evaluations. In subjects with
diabetes, total cholesterol (P=0.003), triglycerides (P=0.004) and
fasting glucose (P=0.016) were significantly higher in carriers of
the variant allele (GC and GG) compared to non-carriers (CC). In
subjects without diabetes, only BMI was higher (P=0.035) in GC
and GG subjects compared to CC.
Discussion
We observed significant associations for two APOC3 SNPs,
m482 and 3u386, with cognitive and metabolic measures in
subjects with diabetes in a Caribbean Hispanic population. For
APOC3 m482, those with diabetes and the AA genotype exhibited
reduced cognitive function, as shown by lower executive function
and lower component test scores (Stroop tests). In contrast, for
Table 2. Cognitive and metabolic measures for APOC3 m482 in Caribbean Hispanics.
Diabetic GG+AG(n=328) AA(n=66) P value
Cognitive Measures
1
Executive Function 20.23160.130 20.55960.167 0.009
Stroop color-naming 41.4461.93 36.9562.46 0.014
Stroop color-word 21.9261.44 18.7661.85 0.022
Stroop word 63.4163.11 58.7863.98 0.117
Memory Function 0.10560.150 0.076160.193 0.844
Attention/concentration 0.15060.151 0.14160.194 0.951
Metabolic Measures
Total cholesterol (mmol/L)
2 4.4060.07 4.7460.14 0.028
LDL-C (mmol/L)
2 2.4460.06 2.6560.12 0.093
Triglyceride (mmol/L)
2 1.7260.01 1.8960.01 0.202
HDL-C (mmol/L)
2 1.0560.02 1.0560.03 0.998
Glucose(mmol/L)
3 8.1260.06 9.0860.06 0.032
BMI (kg/m
2)
4 32.5460.45 34.1360.89 0.094
Non-diabetic GG+AG(n=449) AA(n=117) P value
Cognitive Measures
1
Executive Function 0.29860.065 0.22960.097 0.462
Stroop color-naming 47.5460.96 45.9561.42 0.244
Stroop color-word 25.7860.73 25.3461.08 0.671
Stroop word 73.5261.50 71.7462.23 0.408
Memory Function 0.11660.073 0.21060.108 0.369
Attention/concentration 0.21760.075 0.36860.111 0.163
Metabolic Measures
Total cholesterol (mmol/L)
2 4.8060.06 4.7360.10 0.509
LDL-C (mmol/L)
2 2.8360.05 2.7660.09 0.479
Triglyceride (mmol/L)
2 1.6160.01 1.6060.01 0.874
HDL-C (mmol/L)
2 1.1460.02 1.1360.03 0.893
Glucose(mmol/L)
3 5.4360.06 5.4360.06 0.908
BMI(kg/m
2)
4 30.160.32 29.960.59 0.840
Data are reported as mean6standard error of the mean.
1Adjusted for age, gender, admixture, education and income.
2Adjusted for age, gender, admixture, smoking, drinking, waist circumference, antilipemic medication.
3Adjusted for age, gender, admixture, smoking, drinking, waist circumference.
4Adjusted for age, gender, admixture, smoking, drinking.
doi:10.1371/journal.pone.0005465.t002
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minor allele carriers (GC and GG) with diabetes exhibited higher
plasma triglycerides. For both SNPs, the minor allele in subjects
with diabetes was associated with less favorable cholesterol and
glucose measures, compared to those with diabetes who lacked the
minor allele (G) for the 3u386 SNP and compared to non-
homozygous minor subjects (GG and AG) for the m482 SNP.
Previous studies specifically examining associations between
APOC3 genetic variants and cognition are limited and inconclu-
sive. One early study was negative for an association between the
APOC3 3u386 SNP and familial Alzheimer’s disease in a United
Kingdom population [19], and a second more recent study
reported a weak, protective association of the minor allele of the
3u386 SNP for sporadic Alzheimer’s disease in a Chinese
population [9]. Neither of these studies reported metabolic
measures for their subjects.
Despite limited evidence for associations between APOC3
genotype and cognition, linkages between APOC3 SNPs and the
metabolic dysregulation which may accompany cognitive impair-
ment in older individuals provide potential mechanistic explana-
tions for the associations we observed. Variants of APOC3 3u386
were associated with alterations in lipids, including increased total
cholesterol and triglycerides, and in markers of glucose metabolism
[13,14]. Variants of APOC3 m455 and m482 have been associated
with altered glucose metabolism and metabolic syndrome [15,25].
A fourth APOC3 SNP, m641, has been associated with improved
insulin sensitivity and favorable lipoprotein profiles in Ashkenazi
centenarians and their offspring [3].
Results from the current study are consistent with studies cited
above which reported associations of APOC3 with altered glucose
metabolism. Earlier studies have also reported associations
between diabetes and impaired cognition [18], an association
which is apparent in the current study as well. For subjects with
diabetes in the current study, all three overall cognitive function
scores (executive, memory and attention/concentration) were
significantly lower compared to those without diabetes, indepen-
dently of APOC3 genotype. Within the subset of subjects with
diabetes, lower cognitive function was associated with m482 and
the variant allele of this SNP was also associated with increased
fasting glucose. The IRE location of m482 suggests that this SNP
could render control of transcription of APOC3 sensitive to
changes in glucose metabolism. APOC3 transcription has been
shown to be down-regulated by insulin, but reports differ
regarding the role of the IRE in mediating this process. Genetic
variants of m482 have been shown to be associated with loss of
insulin downregulation of APOC3 transcription [26], but in a
population with familial combined hyperlipidemia, insulin regu-
lation of transcription was shown to be independent of the IRE-
based variants [27]. Subsequent animal studies provided evidence
that insulin inhibition of APOC3 is mediated by nuclear
Table 3. Cognitive and metabolic measures for APOC3 3u386 in Caribbean Hispanics.
Diabetic CC(n=215) GC+GG(n=169) P value
Cognitive Measures
1
Executive Function 20.26260.140 20.28260.142 0.847
Memory Function 0.08060.159 0.13660.161 0.629
Attention/concentration 0.15760.159 0.11160.162 0.694
Metabolic Measures
Total cholesterol (mmol/L)
2 4.2960.09 4.6760.10 0.003
LDL-C (mmol/L)
2 2.4060.07 2.5860.03 0.079
Triglyceride (mmol/L)
2 1.6260.01 1.9160.01 0.004
HDL-C (mmol/L)
2 1.0660.02 1.0560.02 0.865
Glucose(mmol/L)
3 7.9160.06 8.7460.06 0.016
BMI (kg/m
2)
4 32.360.55 33.460.60 0.161
Non-diabetic CC(n=318) GC+GG(n=239) P value
Cognitive Measures
1
Executive Function 0.30860.070 0.25360.082 0.508
Memory Function 0.16160.079 0.07160.092 0.335
Attention/concentration 0.26160.080 0.26060.093 0.992
Metabolic Measures
Total cholesterol (mmol/L)
2 4.7660.07 4.8460.08 0.352
LDL-C (mmol/L)
2 2.7860.06 2.8660.07 0.348
Triglyceride (mmol/L)
2 1.5760.01 1.6860.01 0.184
HDL-C (mmol/L)
2 1.1560.02 1.1260.03 0.334
Glucose(mmol/L)
3 5.4260.06 5.4760.06 0.357
BMI(kg/m
2)
4 29.560.38 30.760.43 0.035
Data are reported as mean6standard error of the mean.
1Adjusted for age, gender, admixture, education and income.
2Adjusted for age, gender, admixture, smoking, drinking, waist circumference, antilipemic medication.
3Adjusted for age, gender, admixture, smoking, drinking, waist circumference.
4Adjusted for age, gender, admixture, smoking, drinking.
doi:10.1371/journal.pone.0005465.t003
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promoter. Elevated Foxo1, which occurs under conditions of both
insulin absence (type 1 diabetes) and insulin resistance (type 2
diabetes), is associated with increased triglyceride production in
mice [28]. Dietary factors (including energy and protein intake)
which modify Foxo1 post-translationally in animals are potential
sources of additional complexity in APOC3 regulation [29].
Further, in the current study population, the chronic hyperglyce-
mia and hyperinsulinemia associated with type 2 diabetes could
impair normal physiologic regulation.
Altered lipid metabolism, like altered glucose metabolism, has
been associated both with APOC3 concentration and also with
altered cognitive ability, although all three variables were not
previously shown to be related. Plasma triglycerides are negatively
correlated with cognitive function in very old individuals [1] and
reducing triglycerides with antilipemic drugs has been shown to
improve cognitive performance [30]. In the current study,
associations with triglycerides were observed for APOC3 3u386
alone, although both 3u386 and m482 were associated with
increased total cholesterol. Increased total cholesterol has been
shown to be a risk factor for dementia/Alzheimer’s disease and
also for milder forms of cognitive impairment, particularly if
cholesterol concentrations are high at mid-life [31].
Both the associations reported for the current study and those
described for other populations depend, in part, on the allelic
frequencies of the APOC3 SNPs we examined, which are highly
variable across ethnic groups. For APOC3 m482, the MAF has
been reported as 0.25 in Whites [of European ancestry], 0.71 in
Africans [of Yoruban ancestry] and 0.44 in South Asians [25]. In
the current study of Caribbean Hispanics, MAF was 0.44. For
APOC3 3u386, MAF has been reported as 0.17 in African-
Americans and 0.095 in Whites [32] but as high as 0.42 in a
hypertriglyceridemic Chinese population [34]. In the current
population, APOC3 3u386 MAF was 0.29. Genetic associations are
also modulated by genetic background, including that of other
SNPs in the APOA1/APOC3/APOA4/APOA5 gene cluster. For
example, the association of APOC3 3u386 with triglycerides was
shown to be not independent of associations of triglycerides with
APOA5 [32] and we cannot eliminate the possibility of similar
relationships in our study population.
The deviation from HWE for the APOC3 3u386 SNP requires
some discussion, because evaluation of HWE has been used as a
tool to detect genotyping error. Genotyping error rates are very
low with the methods we used. Further, HWE deviation may also
reflect population substructure or selection, and may be
interpreted as supportive of an association between genotype
and disease [34]. Results from the genetic neutrality test support
the hypothesis that differences in APOC3 allele frequencies among
populations reflect selective pressures on the APOA1/APOC3 locus
[10,35]. Departure from HWE for the APOC3 3u386 SNP has
been described for other populations, including a sample
composed of French-Canadians and non-French Canadians, in
which the departure appears to be related to different genetic
structures in the two sub-groups [36]. As population stratification
is also an important aspect to the analysis of genetic data of
Caribbean Hispanics, we have adjusted by admixture in our
association testing to reduce confounding associated with popu-
lation sub-structure. Deviation from HWE for this SNP was also
documented for a Korean population comparing hypertriglycer-
idemic and control subjects in which the deviation was due to a
low frequency of homozygosity for the risk allele in control subjects
[37]. Within the APOA1/APOC3/APOA4/APOA5 cluster, devia-
tions from HWE are not always limited to APOC3 3u386 because
other deviations have been reported close to the 39UTR region in
which this SNP is located. In a study investigating twelve APOA1/
APOC3 SNPs in two populations, significant HWE deviations were
present for three SNPs in African-Americans and five SNPs in
European-Americans [38]. Collectively, these results are evidence
of alternative explanations for the observed HWE deviation in our
population.
In summary, our results support an association between APOC3
genotype and cognition in people with diabetes, which may be
mediated through established vascular disease risk factors. Variant
alleles of both APOC3 3u386 and APOC3 m482 were associated
with unfavorable lipid and glucose markers which contribute to
cardiovascular and cerebrovascular disease risk. APOC3 m482 was
also associated with decreased cognitive function. While links
between APOC3 and metabolic dysregulation have been exten-
sively documented, and favorable lipid profiles may be associated
with cognitive health, the observed combined associations between
APOC3 genotype, altered glucose and lipid metabolism and
cognitive function has not been previously reported. Further
research in additional populations, particularly those with a high
prevalence of diabetes, will be needed in order to confirm these
preliminary findings.
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